News - OBI Pharma 台灣浩鼎

2022.Apr.07

Corporate

OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science

2022.Feb.22

Corporate

OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau

2022.Feb.08

未分類

Corporate

OBI Pharma Announces Its In-house COVID-19 Vaccine, BCVax, can induce potent antibodies to neutralize against all variants

2022.Jan.25

Corporate

OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424

2021.Dec.06

未分類

Corporate

OBI Pharma Announces First Cancer Patient Enrolled on OBI-999 in Phase 2 Study

2021.Apr.26

Corporate

OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL

2021.Apr.11

Corporate

Poster Presentation at AACR 2021 Annual Meeting for OBI-3424, OBI-998, GLOBO H and SSEA-4

2021.Apr.06

Corporate

OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4

2021.Jan.06

Corporate

OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference

2020.Nov.23

未分類

Corporate

ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

Announcements

Latest announcements

Events

Latest events